6533b832fe1ef96bd129aef3
RESEARCH PRODUCT
Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study
J.l. CallejaG. NoceaF. ChacónM.á SerraA. Valladaressubject
Pediatricsmedicine.medical_specialtyTotal costbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthTreatment failureTelaprevirchemistry.chemical_compoundchemistryBoceprevirmedicinebusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2013-11-01 | Value in Health |